about
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.Pharmacological management of severe postmenopausal osteoporosis.Hemostatic changes in vasculitides.A systematic review of arterial stiffness, wave reflection and air pollution.Deep vein thrombosis related to environment (Review).Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis.Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease.Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major.Bisphosphonates in the treatment of thalassemia-induced osteoporosis.Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women.Hemostatic effects of diets containing olive or soy oil in hypertensive patients.Pulse wave velocity differs between ulcerative colitis and chronic kidney disease.Pain in Osteoporosis: From Pathophysiology to Therapeutic Approach.Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study.Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.In postmenopausal female subjects with type 2 diabetes mellitus, vertebral fractures are independently associated with cortisol secretion and sensitivity.Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.Anxiety levels predict fracture risk in postmenopausal women assessed for osteoporosis.Peripheral artery disease and osteoporosis: Not only age‑related (Review)The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patientsErratum to: The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patientsPathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical ExperienceThe "lively" cytokines network in beta-Thalassemia Major-related osteoporosisIncreased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone lossAdrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosisThe association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role?Sclerostin is a possible candidate marker of arterial stiffness: Results from a cohort study in CataniaAugmentation index is increased in patients with inflammatory bowel disease, a meta-analysisPaget's bone disease is not always the culpritA suspicious fracture
P50
Q33339910-02B66780-D49B-414E-84E0-8E4A30A5D576Q36132582-CDDA09C7-F3DC-4544-A18A-BA587D5CCA7CQ37518774-5F93ED31-850F-4C59-A763-B32C6141E84DQ38871430-C328BAE2-5C1F-4363-930A-2A4EC264F3CFQ39204609-B98DC986-5A9A-40BC-A90A-25BE4A84F353Q40703352-CB8C108C-5902-4CDA-9A28-83421289669BQ41189137-1FE319CD-6B29-4CFD-9837-65A497C544D8Q41449043-3450A816-7ED2-4BC8-AB7A-78B48B16EFC3Q42044412-B679098C-1A8E-4CF0-95F4-92844B7F58E0Q44104397-45E42F19-6610-406E-9536-BB53A13EECD6Q44174480-069DB47B-62B6-4797-ABFD-9BE0F5F6AE8AQ44445878-E1751374-FB1A-4165-A960-D097EDB690EEQ44659790-A77AAC4E-5C53-4F3F-B68A-30209D15BF4DQ44755610-D35CDF48-6885-420E-8750-BD05D06CEB38Q45213021-520CCB1A-BCFA-4030-ACC1-02DAE50A916EQ47920097-D8CA89B8-0E6C-4FA7-B837-318C55B4C9A0Q48241707-6B8980D4-D9B9-4955-9B94-94E067148FA3Q48603705-A350C96A-BC85-4845-B4DA-3CC44C9C51DEQ50776408-110B3763-0CF7-44E5-98A5-253FF2177E79Q50780694-5B7288D8-098E-4F89-9178-5E8E36B7665AQ51063720-54E1F61E-0C97-4BFA-B803-A3BC3EAB88D2Q51831921-5E016F35-84F2-4575-9191-4D49D37F7898Q53884804-96DC6DFC-8BB9-40BA-BB37-89DB3CE4C195Q57068590-6ED63CE4-20E5-40DB-8B1C-12960F9DCFA4Q60397704-D6ECFDA4-53BE-4F1E-B069-23019CE0138AQ60587248-30A7E7A2-6292-4A8C-9282-0B5FA15CD941Q64971343-0FD04705-B005-41F5-9D9D-2A00B3035DB8Q80107515-BA5F1E43-4095-4C9F-9ABB-8CB8F909AB2DQ83376521-5D94CED1-4C8B-4FA7-8C59-085D0E73008BQ83824713-0B8E2F83-63A5-4329-A961-1968BAFC7E82Q84780556-9818F5CC-89AD-49BB-B115-E5AB5D8D0959Q87662010-74B777F9-282B-4B71-B43B-FCBE2F091BBBQ89223578-907660C6-4645-457C-8F89-61413D646CEFQ89248631-4B204ABB-CD08-43FD-8EE8-A291AFB96257Q90908979-35C015C3-0F52-4098-A681-2BEB70A7F258
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Agostino Gaudio
@ast
Agostino Gaudio
@en
Agostino Gaudio
@es
Agostino Gaudio
@nl
type
label
Agostino Gaudio
@ast
Agostino Gaudio
@en
Agostino Gaudio
@es
Agostino Gaudio
@nl
prefLabel
Agostino Gaudio
@ast
Agostino Gaudio
@en
Agostino Gaudio
@es
Agostino Gaudio
@nl
P106
P1153
7003311964
P21
P31
P496
0000-0002-9958-9606